06:27 , Feb 27, 2019 |  BioCentury  |  Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
19:15 , Feb 22, 2019 |  BC Week In Review  |  Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic...
00:20 , Feb 21, 2019 |  BC Extra  |  Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Wednesday, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic esophagitis....
18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting GM-CSF and MMP9 could help treat breast cancer in obese patients. In an obese genetic mouse model of breast cancer, white adipose tissue (WAT) levels...
04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Calypso, EA Pharma deal

Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The companies will collaborate to develop the human mAb targeting matrix metalloproteinase 9 (MMP9) to treat inflammatory bowel disease (IBD)....
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

Ophthalmic disease INDICATION: Diabetic macular edema (DME) Patient sample and mouse studies suggest inhibiting MMP9 could help treat DME. Levels of MMP9 and a truncated form of the MMP9 substrate NTN1 were higher in vitreous...
07:00 , Jul 11, 2013 |  BC Innovations  |  Cover Story

Debugging Crohn's disease

The intestinal flora of patients with Crohn's disease is frequently populated by adherent-invasive Escherichia coli , which cause intestinal inflammation. Although this inflammatory response is typically treated with tumor necrosis factor -lowering therapies, University of...
07:00 , May 27, 2013 |  BioCentury  |  Emerging Company Profile

Calypso: Fistula fix

Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Calypso Biotech, iDD Biotech deal

iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002 , a humanized mAb, to treat refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties. CALY-002 is in preclinical development,...